Dr. Martens (LON:DOCS) Given “Buy” Rating at Berenberg Bank

Dr. Martens (LON:DOCSGet Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at Berenberg Bank in a research note issued on Wednesday,Digital Look reports. They currently have a GBX 114 price target on the stock. Berenberg Bank’s target price would indicate a potential upside of 76.74% from the stock’s current price.

Separately, Royal Bank Of Canada reiterated a “sector perform” rating on shares of Dr. Martens in a report on Tuesday, February 3rd. Two analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of GBX 3,057.

View Our Latest Report on Dr. Martens

Dr. Martens Trading Up 3.9%

Shares of DOCS opened at GBX 64.50 on Wednesday. Dr. Martens has a 1-year low of GBX 52.50 and a 1-year high of GBX 100.87. The company has a 50-day moving average of GBX 64.79 and a 200 day moving average of GBX 73.36. The firm has a market capitalization of £623.55 million, a price-to-earnings ratio of 37.94, a PEG ratio of 6.40 and a beta of 0.24. The company has a debt-to-equity ratio of 120.66, a current ratio of 2.18 and a quick ratio of 1.13.

Insiders Place Their Bets

In related news, insider Ije Nwokori sold 204,051 shares of Dr. Martens stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of GBX 66, for a total transaction of £134,673.66. In the last three months, insiders have bought 902 shares of company stock worth $60,382. Company insiders own 2.81% of the company’s stock.

Dr. Martens Company Profile

(Get Free Report)

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.

See Also

Receive News & Ratings for Dr. Martens Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Martens and related companies with MarketBeat.com's FREE daily email newsletter.